Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, open-label, four-arm crossover study for CTx-2103 in healthy subjects

Next Previous
Trial Profile

A single-center, open-label, four-arm crossover study for CTx-2103 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buspirone (Primary) ; Buspirone
  • Indications Anxiety disorders
  • Focus Adverse reactions; First in man
  • Sponsors Cingulate Therapeutics

Most Recent Events

  • 09 Apr 2025 According to a Cingulate Therapeutics media release, Company has received a $3 million grant from Private Foundation to accelerate the development of CTx-2103 (buspirone) for the treatment of anxiety.
  • 01 Dec 2023 According to a Cingulate Therapeutics media release, it has received guidance from the Food and Drug Administration (FDA) on advancing its investigational asset CTx-2103 (buspirone) for the treatment of anxiety into clinical development. An Investigational New Drug (IND) application filling expected in the first half of 2024.
  • 10 Mar 2023 According to a Cingulate Therapeutics media release, the positive results from this study provided the critical information required to allow the company to request a Pre-IND meeting with the FDA to discuss the design of the company's clinical and regulatory programs for CTx-2103, which is expected to allow for a potential IND filing in the fourth quarter of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top